CT findings of chemotherapyinduced toxicity: What radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity

Radiology

Volumn 258, Issue 1, 2011, Pages 41-56

  Torrisi, Jean M ^a   Schwartz, Lawrence H ^a   Gollub, Marc J ^a   Ginsberg, Michelle S ^a   Bosl, George J ^a   Hricak, Hedvig ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; ASPARAGINASE; BEVACIZUMAB; BLEOMYCIN; BLEOMYCIN SULFATE; BORTEZOMIB; BUSULFAN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; INTERLEUKIN 2; IRINOTECAN; MELPHALAN; METHOTREXATE; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; RITUXIMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE SULFATE; VINCA ALKALOID; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

BILE DUCT OBSTRUCTION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG TARGETING; FATTY LIVER; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LUNG EDEMA; LUNG HEMORRHAGE; LUNG INFILTRATE; NEUTROPENIA; PATIENT CARE; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; RADIOLOGIST; REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; FEMALE; GASTROINTESTINAL DISEASE; LIVER DISEASE; LUNG DISEASE; MALE; MOLECULARLY TARGETED THERAPY; NEOPLASM; PANCREAS DISEASE; RADIOGRAPHY; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ANTINEOPLASTIC AGENTS; FEMALE; FEMALE UROGENITAL DISEASES; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; LUNG DISEASES; MALE; MALE UROGENITAL DISEASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PANCREATIC DISEASES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES;

EID: 78650628691     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10092129     Document Type: Review

References (113)

1. Bar J, Onn A. Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opin Pharmacother 2008;5(5):701-715.
2. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology (Am Soc Hematol Educ Program) 2007:233-242.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;559(17):1757-1765.
4. Wierzbicki R, Jonker DJ, Moore MJ, et al. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 2009 Oct. 15. [Epub ahead of print]
5. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;50(36):5054-5058.
6. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;50(1):325-334.
7. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;53(4):866-873.
8. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;56(4):525-537.
9. Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006;53(1):98-105.
10. Vander Els NJ, Stover DE. Chemotherapyinduced lung disease. Clin Pulm Med 2004;51(2):84-91.
11. Wittram C, Mark EJ, McLoud TC. CT-histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. RadioGraphics 2003;53(5):1057-1071.
12. Goldiner PL, Carlon GC, Cvitkovic E, Schweizer O, Howland WS. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. BMJ 1978;5(6128):1664-1667.
13. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000;54(6):977-980.
14. Roig J. Pulmonary toxicity caused by cytotoxic drugs. Clin Pulm Med 2006;53(1):53-62.
15. Galvão FH, Pestana JO, Capelozzi VL. Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol 2010;55(3):607-610.
16. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;533(2):528-538. (Pubitemid 351272414)
17. Piccolo F. Oxaliplatin-induced interstitial lung disease. Asia Pac J Clin Oncol 2008;5(3):175-180.
18. Arévalo Lobera S, Sagastibeltza Mariñelarena N, Elejoste Echeberría I, et al. Fatal pneumonitis induced by oxaliplatin. Clin Transl Oncol 2008;50(11):764-767.
19. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;52(12):1875-1880.
20. Cersosimo RJ. Gefitinib: an adverse effects profile. Expert Opin Drug Saf 2006;5(3):469-479.
21. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;5(4):303-306.
22. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006;52(2):135-140.
23. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;53(16):5054-5059.
24. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;52(10):916-919.
25. Herbst RS, O'Neill V J, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;55(30):4743-4750.
26. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;57(9):1405-1412.
27. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;52(11):2184-2191.
28. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997;57(2-3):117-132.
29. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008;5(6):703-716.
30. Biswas S, Nik S, Corrie PG. Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol) 2004;56(8):577-579.
31. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabineinduced systemic capillary leak syndrome. Ann Oncol 2001;52(11):1651-1652.
32. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;509(25):3122-3131.
33. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;52(6):1109-1118.
34. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;50(5):1215-1221.
35. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53(24):2231-2247.
36. Khakoo A Y, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;512(11):2500-2508.
37. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;52(18):3127-3139.
38. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;53(10):1084-1096.
39. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008;53(2):376-381.
40. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;50(5):807-815.
41. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;534(8):494-500.
42. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;53(10):1475-1478.
43. Martín G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007;55(23):3559.
44. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;554(9):980-982; discussion 980-982.
45. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;517(4):292-296.
46. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009;52(1):115-128.
47. Bendix N, Glodny B, Bernathova M, Bodner G. Sonography and CT of vasculitis during gemcitabine therapy. AJR Am J Roentgenol 2005;584(3 suppl):S14-S15.
48. Shahab N, Haider S, Doll DC. Vascular toxicity of antineoplastic agents. Semin Oncol 2006;53(1):121-138.
49. Grenader T, Shavit L, Ospovat I, Gutfeld O, Peretz T. Aortic occlusion in patients treated with Cisplatin-based chemotherapy. Mt Sinai J Med 2006;53(5):810-812.
50. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000;58(10):2169-2178.
51. Vos AH, Splinter TA, van der Heul C. Arterial occlusive events during chemotherapy for germ cell cancer. Neth J Med 2001;59(6):295-299.
52. Cheng E, Berthold DR, Moore MJ, Duran I. Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. Acta Oncol 2009;58(3):475-477.
53. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008;599(6):672-684.
54. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;596(21):2558-2560.
55. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;59(16):1232-1239.
56. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5(4):553-566.
57. Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf 2006;5(2):289-301.
58. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006;53(1):50-67.
59. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;50(suppl 1):S17-S29.
60. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;54(13):2065-2072.
61. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapyassociated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;54(3):274-286.
62. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;500(6):845-853.
63. Blachar A, Federle MP, Brancatelli G. Hepatic capsular retraction: spectrum of benign and malignant etiologies. Abdom Imaging 2002;57(6):690-699.
64. Young ST, Paulson EK, Washington K, Gulliver DJ, Vredenburgh JJ, Baker ME. CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol 1994;563(6):1385-1388.
65. Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV. Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging 2007;51(1):6-10.
66. Fennessy FM, Mortele KJ, Kluckert T, et al. Hepatic capsular retraction in metastatic carcinoma of the breast occurring with increase or decrease in size of subjacent metastasis. AJR Am J Roentgenol 2004;582(3):651-655.
67. Anderson SD, Holley HC, Berland LL, Van Dyke JA, Stanley RJ. Causes of jaundice during hepatic artery infusion chemotherapy. Radiology 1986;561(2):439-442.
68. Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA, Charnsangavej C. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin Radiol 2005;50(6):700-709.
69. Botet JF, Watson RC, Kemeny N, Daly JM, Yeh S. Cholangitis complicating intraarterial chemotherapy in liver metastasis. Radiology 1985;556(2):335-337.
70. Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur Radiol 2009;59(7):1752-1762.
71. Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic venoocclusive disease: current status and novel approaches. Br J Haematol 1999;507(3):485-493.
72. Lassau N, Leclère J, Auperin A, et al. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Radiology 1997;504(2):545-552.
73. Erturk SM, Mortelé KJ, Binkert CA, et al. CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. AJR Am J Roentgenol 2006;586(6):1497-1501.
74. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;55(3):460-466.
75. Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009;5(4):225-230.
76. Tisman G, MacDonald D, Shindell N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 2004;52(15):3202-3204.
77. McDonald GB, Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West J Med 1984;540(2):250-259.
78. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;595(21):2516-2524.
79. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007;500(9):909-911.
80. Amar S, Wu KJ, Tan WW. Sorafenibinduced pancreatitis. Mayo Clin Proc 2007;52(4):521.
81. Kelvin FM, Gramm HF, Gluck WL, Lokich JJ. Radiologic manifestations of small-bowel toxicity due to floxuridine therapy. AJR Am J Roentgenol 1986;546(1):39-43.
82. Hiehle JF Jr, Levine MS. Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. Can Assoc Radiol J 1991;52(2):109-112.
83. Zamani R, Heldmann M. Enteritis as a complication of adjuvant combination chemotherapy using 5-fluorouracil and leukovorin: clinical and helical computed tomographic features. J la State Med Soc 2004;556(3):143-144.
84. Hall DA, Clouse ME, Gramm HF. Gastroduodenal ulceration after hepatic arterial infusion chemotherapy. AJR Am J Roentgenol 1981;536(6):1216-1218.
85. Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984;5(6):595-600.
86. Hohn DC, Stagg RJ, Price DC, Lewis BJ. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′-deoxyuridine. J Clin Oncol 1985;5(9):1257-1260.
87. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;59(18):3801-3807.
88. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009;5009:567486.
89. Asnacios A, Naveau S, Perlemuter G. Gastrointestinal toxicities of novel agents in cancer therapy. Eur J Cancer 2009;55(suppl 1):332-342.
90. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;52(12):1443-1455.
91. Wade DS, Nava HR, Douglass HO Jr. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 1992;59(1):17-23.
92. Dosik GM, Luna M, Valdivieso M, et al. Necrotizing colitis in patients with cancer. Am J Med 1979;57(4):646-656.
93. Galm O, Fabry U, Adam G, Osieka R. Pneumatosis intestinalis following cytotoxic or immunosuppressive treatment. Digestion 2001;54(2):128-132.
94. St Peter SD, Abbas MA, Kelly KA. The spectrum of pneumatosis intestinalis. Arch Surg 2003;538(1):68-75.
95. Hashimoto S, Saitoh H, Wada K, et al. Pneumatosis cystoides intestinalis after chemotherapy for hematological malignancies: report of 4 cases. Intern Med 1995;54(3):212-215.
96. Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 2008;56(1):95-96.
97. Kung D, Ruan DT, Chan RK, Ericsson ML, Saund MS. Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin. Dig Dis Sci 2008;53(1):217-219.
98. Wiesner W, Mortelé KJ, Glickman JN, Ji H, Ros PR. Pneumatosis intestinalis and portomesenteric venous gas in intestinal ischemia: correlation of CT findings with severity of ischemia and clinical outcome. AJR Am J Roentgenol 2001;577(6):1319-1323.
99. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;505(1):3-6.
100. REPEAT OF REFERENCE 56.
101. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;53(5 suppl 10):S26-S34.
102. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;54(6):1860-1869.
103. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007;507(1):118-123.
104. Rosenberg RF, Caridi JG. Vincristineinduced megacolon. Gastrointest Radiol 1983;5(1):71-73.
105. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. RadioGraphics 2006;56(2):481-495.
106. de Jonge MJ, Verweij J. Renal toxicities of chemotherapy. Semin Oncol 2006;53(1):68-73.
107. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;516(8):546-554.
108. Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Target Oncol 2009;5(2):121-133.
109. Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D. Urological implications of cyclophosphamide and ifosfamide. Scand J Urol Nephrol 2008;52(4):309-317.
110. Shimura K, Shimazaki C, Taniguchi K, Inaba T, Horiike S, Taniwaki M. Bortezomibinduced neurogenic bladder in patients with multiple myeloma. Ann Hematol 2009;58(4):383-384.
111. Wheeler JS Jr, Siroky MB, Bell R, Babayan RK. Vincristine-induced bladder neuropathy. J Urol 1983;530(2):342-343.
112. Chen JP, Lo Y, Yu CJ, Hsu C, Shih JY, Yang CH. Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. Lung Cancer 2008;50(1):92-97.
113. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998;56(10):3426-3432.